*Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Departments of †Global Health
§Biostatistics, University of Washington, Seattle, WA
¶Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
‖Makerere University, Johns Hopkins University Research Collaboration, Kampala, Uganda
**University of Zimbabwe, Harare, Zimbabwe
††South African Medical Research Council, Durban, South Africa
‡‡Medical College of Malawi—Johns Hopkins University Research Collaboration, Blantyre, Malawi
§§Emavundleni Research Centre, Cape Town, South Africa
¶¶Department of Medicine, University of Washington, Seattle, WA
This research was funded in part by a grant from the U.S. National Institutes of Health (NIH) (R03MH106352) and a 2014 developmental grant from the University of Washington Center for AIDS Research (CFAR), an NIH-funded program under award number P30AI027757, which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, and NIDDK). The Microbicide Trials Network (MTN) is funded by NIAID (UM1AI068633, UM1AI068615, and UM1AI106707), with co-funding from NICHD and NIMH, all components of the NIH.
Presented in part at the HIV Research for Prevention Conference; October 17–20, 2016; Chicago, IL.
The authors have no conflicts of interest to disclose.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.